Rekah Pharmaceutical Industry Stock Shares Owned By Institutions
| REKA Stock | ILA 1,422 16.00 1.11% |
Rekah Pharmaceutical Industry fundamentals help investors to digest information that contributes to Rekah Pharmaceutical's financial success or failures. It also enables traders to predict the movement of Rekah Stock. The fundamental analysis module provides a way to measure Rekah Pharmaceutical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Rekah Pharmaceutical stock.
Rekah |
Rekah Pharmaceutical Industry Company Shares Owned By Institutions Analysis
Rekah Pharmaceutical's Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
More About Shares Owned By Institutions | All Equity Analysis
Shares Held by Institutions | = | Funds and Banks | + | Firms |
Current Rekah Pharmaceutical Shares Owned By Institutions | 42.66 % |
Most of Rekah Pharmaceutical's fundamental indicators, such as Shares Owned By Institutions, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Rekah Pharmaceutical Industry is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.
| Competition |
Based on the latest financial disclosure, 42.657% of Rekah Pharmaceutical Industry are shares owned by institutions. This is 4.44% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The shares owned by institutions for all Israel stocks is 8.79% lower than that of the firm.
Rekah Shares Owned By Institutions Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Rekah Pharmaceutical's direct or indirect competition against its Shares Owned By Institutions to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Rekah Pharmaceutical could also be used in its relative valuation, which is a method of valuing Rekah Pharmaceutical by comparing valuation metrics of similar companies.Rekah Pharmaceutical is currently under evaluation in shares owned by institutions category among its peers.
Rekah Fundamentals
| Return On Equity | 0.0222 | |||
| Return On Asset | 0.0208 | |||
| Profit Margin | 0.01 % | |||
| Operating Margin | 0.05 % | |||
| Current Valuation | 316.92 M | |||
| Shares Outstanding | 11.41 M | |||
| Shares Owned By Insiders | 37.27 % | |||
| Shares Owned By Institutions | 42.66 % | |||
| Price To Book | 1.11 X | |||
| Price To Sales | 0.63 X | |||
| Revenue | 263.95 M | |||
| Gross Profit | 65.16 M | |||
| EBITDA | 36.2 M | |||
| Net Income | 6.62 M | |||
| Cash And Equivalents | 31.61 M | |||
| Cash Per Share | 2.77 X | |||
| Total Debt | 101.23 M | |||
| Debt To Equity | 1.01 % | |||
| Current Ratio | 1.99 X | |||
| Book Value Per Share | 14.39 X | |||
| Cash Flow From Operations | 21.17 M | |||
| Earnings Per Share | 0.32 X | |||
| Number Of Employees | 399 | |||
| Beta | 0.0605 | |||
| Market Capitalization | 193.93 M | |||
| Total Asset | 437.09 M | |||
| Retained Earnings | 49 M | |||
| Working Capital | 156 M | |||
| Current Asset | 246 M | |||
| Current Liabilities | 90 M | |||
| Z Score | 0.6 | |||
| Annual Yield | 0.05 % | |||
| Net Asset | 437.09 M | |||
| Last Dividend Paid | 0.87 |
About Rekah Pharmaceutical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Rekah Pharmaceutical Industry's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Rekah Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Rekah Pharmaceutical Industry based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Rekah Stock
Rekah Pharmaceutical financial ratios help investors to determine whether Rekah Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Rekah with respect to the benefits of owning Rekah Pharmaceutical security.